ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
ALXO Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
ALX Oncology Holdings Inc.NASDAQ: ALXO
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses declines year over year
Q1 FY2026 operating expenses of $18.82M fell 40.9% year over year, behind the -33.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 18.3% from the prior quarter. Over 3 fiscal years it compounded at -6.5% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.9% toward the trailing-twelve-month pace of -33.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 104.02M USD
- Year-over-year change
- -27.0%
- 4-year CAGR
- +5.6%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 104.02M | -27.0% |
| FY2024 | 2024-12-31 | 142.47M | -16.3% |
| FY2023 | 2023-12-31 | 170.28M | +33.6% |
| FY2022 | 2022-12-31 | 127.44M | +52.5% |
| FY2021 | 2021-12-31 | 83.56M | — |
Operating Expenses vs competitors
How ALXO compares with its peers on the latest reported figures
- ALXO's LTM Mar 2026 operating expenses of $91.02M is the 7th highest of the 8 companies compared; the peer median is $203.15M.
- Its year-over-year change of -33.2% is the lowest of 8, against a peer median of +18.6%.
- Over three fiscal years its annual growth of -6.5% compares with a peer median of +14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $457.25M | +29.0% | +23.1% | 435.5% | |
| LTM Mar 2026 | $234.87M | +104.1% | +34.7% | 369.9% | |
| LTM Mar 2026 | $214.24M | +41.4% | +20.6% | 667.8% | |
| LTM Mar 2026 | $203.15M | +11.1% | +13.5% | — | |
| LTM Mar 2026 | $189.2M | +18.6% | +14.7% | 440.5% | |
| LTM Mar 2026 | $113.97M | -13.7% | -2.0% | — | |
| LTM Mar 2026 | $91.02M | -33.2% | -6.5% | — | |
| LTM Mar 2026 | $86.18M | -19.9% | -10.1% | 38304.0% | |
| Peer median (excluding ALXO) | $203.15M | +18.6% | +14.7% | 440.5% | |
Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 60.17M | 98.4M | 141.8M | 116.37M | 77M |
| Selling, General & Admin | 23.39M | 29.04M | 28.48M | 26.09M | 23.85M |
| Operating Expenses | 83.56M | 127.44M | 170.28M | 142.47M | 104.02M |
| Depreciation & Amortization | 51K | 342K | 836K | 872K | 706K |
| EBITDA | (83.42M) | (122.84M) | (158.4M) | (132.25M) | (99.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.56M) | (127.44M) | (170.28M) | (142.47M) | (104.02M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 91 | 4.28M | 10.65M | 9.37M | 3.96M |
| Interest Expense | 13K | 238K | 1.57M | 1.73M | 1.6M |
| Other Income / Expenses | 71K | 4.02M | 9.47M | 7.62M | 2.33M |
| Income Before Tax | (83.48M) | (123.42M) | (160.81M) | (134.85M) | (101.7M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | 64K | 0 | 0 | 0 |
| Net Income | (83.46M) | (123.48M) | (160.81M) | (134.85M) | (101.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| EPS (Diluted) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| Weighted Avg Shares | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
| Weighted Avg Shares (Diluted) | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
ALX Oncology Holdings Inc.
NASDAQ:ALXO
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.